Search

Your search keyword '"Dey, Jyotirmoy"' showing total 133 results

Search Constraints

Start Over You searched for: Author "Dey, Jyotirmoy" Remove constraint Author: "Dey, Jyotirmoy"
133 results on '"Dey, Jyotirmoy"'

Search Results

1. A multi-wavelength study of Galactic H II regions with extended emission

2. Gas dynamics in the star forming region G18.148$-$0.283: Is it a manifestation of two colliding molecular clouds?

3. Assessing contribution of treatment phases through tipping point analyses via counterfactual elicitation using rank preserving structural failure time models

4. Angular power spectrum of supernova remnants: effects of structure, geometry and diffuse foreground

5. Assessing contribution of treatment phases through tipping point analyses using rank preserving structural failure time models

6. Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic

7. Late-Stage C–H Deuteration of Organic Compounds via Ligand-Enabled Palladium-Catalyzed Hydrogen Isotope Exchange.

11. Palladium(II)‐Catalyzed Nondirected Late‐Stage C(sp2)−H Deuteration of Heteroarenes Enabled Through a Multi‐Substrate Screening Approach.

12. Palladium(II)‐katalysierte nicht‐dirigierte late‐stage C(sp2)−H Deuterierung von Heteroaromaten ermöglicht über einen Multi‐Substrat‐Screening‐Ansatz.

17. Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

18. Assessing Contribution of Treatment Phases through Tipping Point Analyses via Counterfactual Elicitation Using Rank Preserving Structural Failure Time Models.

19. A framework for assessing the impact of accelerated approval

21. Estimands for overall survival in clinical trials with treatment switching in oncology

22. Estimands in Clinical Trials with Treatment Switching

23. Zinc‐bis(imino)pyridine Complexes as Catalysts for Azide‐Alkyne Cycloaddition in Water.

24. Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

25. Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

29. Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic

30. Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

33. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

36. Gas Dynamics in the Star-forming Region G18.148â€"0.283: Is It a Manifestation of Two Colliding Molecular Clouds?

37. Estimands for overall survival in clinical trials with treatment switching in oncology.

39. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

43. Stabilization of ultra-small gold nanoparticles in a photochromic organic cage: modulating photocatalytic CO2 reduction by tuning light irradiation.

44. Angular power spectrum of supernova remnants: effects of structure, geometry, and diffuse foreground.

45. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.

47. ACTR-39. TWO-YEAR RESULTS OF THE INTELLANCE 2/EORTC TRIAL 1410 RANDOMIZED PHASE II STUDY ON DEPATUX–M ALONE, DEPATUX-M COMBINED WITH TEMOZOLOMIDE (TMZ) AND EITHER TMZ OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA (NCT02343406

48. Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).

49. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy

50. Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592)

Catalog

Books, media, physical & digital resources